Skip to content

Kentucky Medicaid

Does Kentucky Medicaid cover Zepbound for Obstructive Sleep Apnea (OSA)?

Yes. Kentucky Medicaid covers Zepbound for obstructive sleep apnea (OSA) with prior authorization if your BMI is 30 or higher. Other policy requirements and your plan's benefits also apply.

Policy document

  • Medicaid: Covered with requirements. See the qualification pathways below.

Earliest policy review June 4, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Medicaid plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

Initial Approval — Moderate-to-Severe OSA with Obesity

All of:

  • Diagnosis of moderate to severe obstructive sleep apnea (OSA)
  • BMI ≥ 30 kg/m2
  • Prescriber documentation of patient's baseline weight
  • Prescribed by or in consultation with a neurologist, sleep specialist, or other OSA specialist
  • Trial ≥ 3 months AND failure, contraindication, or intolerance of at least ONE PAP device (APAP, BiPAP, or CPAP)
  • Documentation that medication will be used with reduced calorie diet and increased physical activity
  • No history of diabetes
  • Current A1C < 6.5%
  • No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Requested dose does not exceed maximum FDA-approved dose
  • Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist

Plus any one of:

  • AHI/RDI/REI ≥ 15 events/hour that is predominantly obstructive
  • AHI/RDI/REI ≥ 5 events/hour WITH at least ONE typical OSA symptom (unrefreshing sleep, daytime sleepiness, fatigue, insomnia, awakening with gasping/choking, loud snoring, or witnessed apneas)

Renewal — Continued OSA Treatment

All of:

  • Diagnosis of moderate to severe OSA and obesity
  • Prescribed by or in consultation with a neurologist, sleep specialist, or other OSA specialist
  • Documentation that medication will continue to be used with reduced calorie diet and increased physical activity
  • No history of diabetes
  • Current A1C < 6.5%
  • No personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
  • Requested dose does not exceed maximum FDA-approved dose
  • Not used in combination with another GLP-1 or dual GLP-1/GIP receptor agonist

Plus any one of:

  • Reduction in AHI/RDI/REI by ≥ 15 events/hour
  • Reduction in AHI/RDI/REI by ≥ 50%

Documentation to bring

  • Progress notes documenting confirmed diagnosis of moderate to severe OSA
  • AHI/RDI/REI value confirming ≥ 15 events/hour (predominantly obstructive) OR ≥ 5 events/hour with at least one typical OSA symptom
  • Documentation of BMI ≥ 30 kg/m2
  • Documentation of patient's baseline weight
  • Confirmation that prescriber is or has consulted with a neurologist, sleep specialist, or other OSA specialist
  • Documentation of ≥ 3-month trial with failure, contraindication, or intolerance of APAP, BiPAP, or CPAP
  • Prescriber attestation that medication will be used with reduced calorie diet and increased physical activity
  • Documentation confirming no history of diabetes
  • Current A1C result confirming < 6.5%
  • Confirmation of no personal or family history of MTC or MEN 2
  • For renewal: AHI/RDI/REI result showing ≥ 15 events/hour reduction or ≥ 50% reduction
  • For renewal: Documentation of ≥ 5% reduction in baseline body weight OR documentation assessing lifestyle and diet interventions if weight loss goal not met

Quantity limits

  • all strengths — 4 pens (2 mL) per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Renewal requires: (1) reduction in AHI/RDI/REI by ≥15 events/hour OR ≥50%; AND (2) at least 5% reduction in baseline body weight OR documentation assessing lifestyle and diet interventions if weight loss goal not met. Diabetes exclusion (history of diabetes or A1C ≥6.5%) is re-verified at renewal. PAP trial requirement is NOT re-checked at renewal.

Not covered when

  • History of diabetes (any type)
  • Current A1C ≥ 6.5%
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Concomitant use of another GLP-1 or dual GLP-1/GIP receptor agonist

Policy note: This policy is for the OSA indication only. The document excludes patients with a history of diabetes OR current A1C ≥ 6.5%, making this a non-diabetic OSA population only. PAP device trial (APAP, BiPAP, or CPAP) for ≥ 3 months with failure, contraindication, or intolerance is required before approval. The AHI lower threshold pathway (AHI ≥ 5) requires at least one typical OSA symptom. At renewal, the AHI improvement threshold (≥15 events/hour OR ≥50% reduction) must be documented. Weight loss of ≥ 5% from baseline is the renewal weight threshold, but if not met, documentation of lifestyle/diet interventions is an acceptable alternative. Managed by MedImpact Healthcare Systems on behalf of Kentucky Medicaid. Copyright 2025 MedImpact Healthcare Systems, Inc.

verified June 4, 2026 · source: Zepbound PA Criteria · View policy document (PDF)

Open on its own page →

Questions people ask
Does Kentucky Medicaid cover Zepbound?
Yes. Kentucky Medicaid covers Zepbound for obstructive sleep apnea (OSA) with prior authorization if your BMI is 30 or higher. Other policy requirements and your plan's benefits also apply.
How long does a Zepbound approval last with Kentucky Medicaid?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. Initial approval: 6 months. Renewal: every 6 months.
What does Kentucky Medicaid require to renew Zepbound?
Obstructive Sleep Apnea (OSA) — Applies to Medicaid plans. Renewal requires: (1) reduction in AHI/RDI/REI by ≥15 events/hour OR ≥50%; AND (2) at least 5% reduction in baseline body weight OR documentation assessing lifestyle and diet interventions if weight loss goal not met. Diabetes exclusion (history of diabetes or A1C ≥6.5%) is re-verified at renewal. PAP trial requirement is NOT re-checked at renewal.
How current is this information?
The oldest review date among the policies on this page is June 4, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Kentucky Medicaid: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Elevance Health, Alabama Medicaid, California Medicaid, Colorado Medicaid, Connecticut Medicaid, Delaware Medicaid, Illinois Medicaid, Indiana Medicaid

All insurance plans · All medications

Summary of Kentucky Medicaid's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.